Metagenomic Sequencing Proposed for Respiratory Tract Infection Detection
By LabMedica International staff writers Posted on 13 Dec 2018 |
Image: The HiSeq 4000 Systems leverage innovative patterned flow cell technology to provide rapid, high-performance sequencing. Perform production-scale, high-throughput exome or transcriptome sequencing projects quickly and economically (Photo courtesy of Illumina).
Lower respiratory tract infections (LRTIs) are the leading cause of infectious disease-related deaths worldwide yet remains challenging to diagnose because of limitations in existing microbiologic tests.
In critically ill patients, noninfectious respiratory syndromes that resemble LRTIs further complicate diagnosis and confound targeted treatment. A sequencing-based strategy has been developed for simultaneously assessing pathogen, microbiome, and host response features to potentially diagnose individuals with lower respiratory tract infections.
A multidisciplinary team of scientists at the University of California, San Francisco (CA, USA) performed a prospective observational study that evaluated 92 adults with acute respiratory failure requiring mechanical ventilation who were admitted to the University of California, San Francisco (UCSF) Moffitt–Long Hospital ICUs. Subjects were enrolled sequentially between July 25, 2013, and October 17, 2017, within the first 72 hours of intubation for respiratory failure.
During the period of study enrollment, subjects received standard of care microbiologic testing ordered by the treating clinicians. Respiratory testing from bronchial alveolar lavage (BAL), or mini-BAL included: bacterial and fungal stains and semi-quantitative cultures for AFB stains and cultures (n = 8); 12-target clinical multiplex polymerase chain reaction for influenza A/B, respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human rhinovirus (HRV), adenovirus (ADV), and 23 parainfluenza viruses (PIV) 1–4. Other microbiologic testing included 89 blood culture; 87 urine culture; four serum cryptococcal antigen; one serum galactomannan; and serum β-d-glucan. RNA-seq and DNA-seq libraries underwent 125-nt paired-end Illumina sequencing on a HiSeq 4000.
The scientists used rules-based and logistic regression computational models aimed at assaying for lung pathogens based on the DNA and RNA features gleaned from the metagenomic data. They initially tested the algorithms on 20 patients with or without acute lower respiratory tract infections, who had relatively clear diagnoses from the outset. They subsequently validated the models using data for another two dozen individuals, where they could detect lower respiratory tract infections with nearly 96% accuracy before taking the approach forward to a larger group of patients.
The authors concluded that they had addressed the need for better lower respiratory tract infection diagnostics by developing a metagenomic next-generation sequencing-based method that integrates host response and unbiased microbe detection. They then evaluated the performance of this approach in a prospective cohort of critically ill patients with acute respiratory failure. From these data, they suggested that it is possible to bring together pathogen, microbiome diversity, and host gene expression metrics to identify LRTI-positive patients and differentiate them from critically ill controls with non-infectious acute respiratory illnesses. The study was published on November 27, 2018, in the journal Proceedings of the National Academy of Sciences.
Related Links:
University of California, San Francisco
In critically ill patients, noninfectious respiratory syndromes that resemble LRTIs further complicate diagnosis and confound targeted treatment. A sequencing-based strategy has been developed for simultaneously assessing pathogen, microbiome, and host response features to potentially diagnose individuals with lower respiratory tract infections.
A multidisciplinary team of scientists at the University of California, San Francisco (CA, USA) performed a prospective observational study that evaluated 92 adults with acute respiratory failure requiring mechanical ventilation who were admitted to the University of California, San Francisco (UCSF) Moffitt–Long Hospital ICUs. Subjects were enrolled sequentially between July 25, 2013, and October 17, 2017, within the first 72 hours of intubation for respiratory failure.
During the period of study enrollment, subjects received standard of care microbiologic testing ordered by the treating clinicians. Respiratory testing from bronchial alveolar lavage (BAL), or mini-BAL included: bacterial and fungal stains and semi-quantitative cultures for AFB stains and cultures (n = 8); 12-target clinical multiplex polymerase chain reaction for influenza A/B, respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human rhinovirus (HRV), adenovirus (ADV), and 23 parainfluenza viruses (PIV) 1–4. Other microbiologic testing included 89 blood culture; 87 urine culture; four serum cryptococcal antigen; one serum galactomannan; and serum β-d-glucan. RNA-seq and DNA-seq libraries underwent 125-nt paired-end Illumina sequencing on a HiSeq 4000.
The scientists used rules-based and logistic regression computational models aimed at assaying for lung pathogens based on the DNA and RNA features gleaned from the metagenomic data. They initially tested the algorithms on 20 patients with or without acute lower respiratory tract infections, who had relatively clear diagnoses from the outset. They subsequently validated the models using data for another two dozen individuals, where they could detect lower respiratory tract infections with nearly 96% accuracy before taking the approach forward to a larger group of patients.
The authors concluded that they had addressed the need for better lower respiratory tract infection diagnostics by developing a metagenomic next-generation sequencing-based method that integrates host response and unbiased microbe detection. They then evaluated the performance of this approach in a prospective cohort of critically ill patients with acute respiratory failure. From these data, they suggested that it is possible to bring together pathogen, microbiome diversity, and host gene expression metrics to identify LRTI-positive patients and differentiate them from critically ill controls with non-infectious acute respiratory illnesses. The study was published on November 27, 2018, in the journal Proceedings of the National Academy of Sciences.
Related Links:
University of California, San Francisco
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans